Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Clin Cancer Res. 2019 Apr 16;25(19):5735–5742. doi: 10.1158/1078-0432.CCR-18-0836

Table 1:

Classification of BRAF mutations

BRAF Class BRAF mutation Kinase activity Potential targets
Class I V600 RAS-independent BRAFi or BRAFi/MEKi combination
Class II non-V600 RAS and RTK independent MEKi, ERKi or paradoxical blocking BRAFi
Class III N581, D594 No kinase activity, CRAF activation. MEKi+ RTK inhibitors